CKD Staging (KDIGO 2012)
Stages chronic kidney disease (CKD) by GFR category (G1-G5) and albuminuria category (A1-A3) per KDIGO 2012 guidelines.
Score interpretation
G1–G2 with A1. If there are no other markers of kidney damage, this is not CKD.
→ If CKD (other markers of kidney damage present): eGFR and ACR at least once a year (KDIGO); manage cardiovascular risk.
G1–G2 with A2, or G3a with A1.
→ eGFR and ACR at least once a year; blood pressure to target; ACE inhibitor / ARB if albuminuric with diabetes or hypertension; review nephrotoxic drugs.
G1–G2 with A3, G3a with A2, or G3b with A1.
→ eGFR and ACR about twice a year; RAS blockade and an SGLT2 inhibitor where indicated; ACR ≥ 30 mg/mmol (A3) is a KDIGO criterion for nephrology referral.
G3a with A3, G3b with A2–A3, or G4–G5 with any albuminuria.
→ eGFR and ACR 3–4 or more times a year; nephrology care (eGFR < 30 is a referral criterion); plan for kidney failure (dialysis, transplant or conservative care) as eGFR falls.
Interpretation bands for the CKD Stage (KDIGO). Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.